SAB Biotherapeutics Inc expected to post a loss of 4 cents a share - Earnings Preview

SAB Biotherapeutics

24/03/2023 11:07

* SAB Biotherapeutics Inc  SABS.OQ   SABS.O  is expected
to show a
fall in quarterly revenue when it reports  results on March 27
(estimated). 
    * The Sioux Falls South Dakota-based  company is expected to
report  a 89.3% decrease in revenue to $6.504 million from
$60.88 million a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for SAB Biotherapeutics
Inc
is for a loss of 4 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for SAB
Biotherapeutics Inc is $4​, above​ its last closing price
of $0.50. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.19       -0.16      -0.16     Met     0
 Jun. 30 2022  -0.17       -0.17      -0.11     Beat    35.3
 Mar. 31 2022  -0.17       -0.16      0.02      Beat    112.1​
 Dec. 31 2021  -0.10       -0.11      -0.66     Missed  -500
 ​​Sep.        -0.10       -0.09      -0.02     Beat    76.9
 30 2021                                                
                                                        ​
 This summary was machine generated March 24 at 11:07 GMT.  All
figures in US dollars  unless otherwise stated